SCHEMBL6221900

SCHEMBL6221900

O=C(Cl)c1cccc2occc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.47
FTO Q9C0B1 2/20 0.47
MAOA P21397 2/20 0.47
MRGPRX1 Q96LB2 1/20 0.40
ALDH1A1 P00352 3/20 0.39
ALOX15 P16050 1/20 0.39
MTNR1A P48039 2/20 0.37
MTNR1B P49286 2/20 0.37
FADS1 O60427 1/20 0.36
CYP1A1 P04798 3/20 0.35
CYP1B1 Q16678 3/20 0.35
CYP1A2 P05177 1/20 0.35
KCNA3 P22001 1/20 0.35
ABCB1 P08183 1/20 0.35
OPRM1 P35372 1/20 0.34
OPRK1 P41145 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL269277 0.82 MAOB (0.49) MAOBFTOMAOAMRGPRX1ALDH1A1
SCHEMBL30669447 0.81 ALDH1A1 (0.46) MAOBFTOMAOAMRGPRX1ALDH1A1
SCHEMBL827158 0.81 ALDH1A1 (0.46) MAOBFTOMAOAMRGPRX1ALDH1A1
SCHEMBL827785 0.81 MAOB (0.42) MAOBFTOMAOAMRGPRX1ALDH1A1
SCHEMBL4215092 0.78 MAOB (0.44) MAOBFTOMAOAMRGPRX1ALDH1A1
SCHEMBL1380870 0.77 PLK1 (0.54) MAOBFTOMAOAMRGPRX1MTNR1A
SCHEMBL7699866 0.77 MTNR1A (0.43) MAOBFTOMAOAMRGPRX1ALDH1A1
SCHEMBL826486 0.77 LMNA (0.46) MRGPRX1ALDH1A1ALOX15MTNR1AMTNR1B
SCHEMBL28782405 0.75 KMT2A (0.43) MAOBFTOMAOAMRGPRX1ALDH1A1
SCHEMBL87682 0.74 MAOB (0.58) MAOBMAOAALOX15HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289955-B1 PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2005-04-13 EP disclosed
US-6677354-B2 TREATING SLEEP, BRAIN, SEXUAL, CARDIOVASCULAR, NERVOUS SYSTEM, PSYCHOLOGICAL, GLANDULAR, AND GASTROINTESTINAL DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2004-01-13 US disclosed
US-20030186964-A1 Piperdines for use as orexin receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-02 US disclosed
EP-1289955-A1 PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2003-03-12 EP disclosed
WO-2001096302-A1 PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM P.L.C. (GB) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186964-A1 Piperdines for use as orexin receptor antagonists HCRTR2, HCRTR1, NPSR1 MAOB 330/4885FTO 2210/4885MAOA 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.